Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Ultragenyx Pharmaceutical Inc’s stock clocked out at $30.95, down -2.89% from its previous closing price of $31.87. In other words, the price has decreased by -$2.89 from its previous closing price. On the day, 1.8 million shares were traded. RARE stock price reached its highest trading level at $31.88 during the session, while it also had its lowest trading level at $30.055.
Ratios:
To gain a deeper understanding of RARE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 13 ’25 when Horn Howard sold 7,942 shares for $31.51 per share. The transaction valued at 250,252 led to the insider holds 98,227 shares of the business.
Huizenga Theodore Alan sold 64 shares of RARE for $1,867 on Sep 18 ’25. The SVP, Chief Accounting Officer now owns 50,242 shares after completing the transaction at $29.17 per share. On Sep 12 ’25, another insider, KARAH PARSCHAUER, who serves as the Officer of the company, bought 2,450 shares for $31.17 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2985980928 and an Enterprise Value of 3379670016. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.73 while its Price-to-Book (P/B) ratio in mrq is 325.31. Its current Enterprise Value per Revenue stands at 5.359 whereas that against EBITDA is -6.639.
Stock Price History:
The Beta on a monthly basis for RARE is 0.17, which has changed by -0.36715645 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $53.47, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -1.62%, while the 200-Day Moving Average is calculated to be -11.42%.
Shares Statistics:
It appears that RARE traded 1.54M shares on average per day over the past three months and 1437300 shares per day over the past ten days. A total of 96.27M shares are outstanding, with a floating share count of 89.55M. Insiders hold about 7.07% of the company’s shares, while institutions hold 95.18% stake in the company. Shares short for RARE as of 1760486400 were 8692947 with a Short Ratio of 5.64, compared to 1757894400 on 7947955. Therefore, it implies a Short% of Shares Outstanding of 8692947 and a Short% of Float of 9.34.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Ultragenyx Pharmaceutical Inc (RARE).The consensus estimate for the next quarter is -$1.33, with high estimates of -$1.04 and low estimates of -$1.74.
Analysts are recommending an EPS of between -$5.65 and -$5.84 for the fiscal current year, implying an average EPS of -$5.72. EPS for the following year is -$3.98, with 12.0 analysts recommending between -$1.06 and -$5.57.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $185.17M. It ranges from a high estimate of $197M to a low estimate of $168.15M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 15 analysts are estimating revenue of $172.51M. There is a high estimate of $198.2M for the next quarter, whereas the lowest estimate is $146M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.56M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $800.27M in the next fiscal year. The high estimate is $901.1M and the low estimate is $673.2M.
